Ependymomas: development of immunotherapeutic strategies

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.2013.840420PMID 24117271PMCID PMC3972122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptide vaccine therapy for childhood gliomas.

  2013cited by this paper
• Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

  2012cited by this paper
• Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas

  2012cited by this paper
• Do we need novel radiologic response criteria for brain tumor immunotherapy?

  2011cited by this paper
• MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study

  2011cited by this paper
• A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.

  2011cited by this paper
• Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

  2011cited by this paper
• Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

  2011cited by this paper
• Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

  2010cited by this paper
• Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Cross-species genomics matches driver mutations and cell compartments to model ependymoma

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Ependymomas in Adults

  2010cited by this paper
• Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours

  2010cited by this paper
• Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study.

  2009cited by this paper
• Immunotherapeutic approaches for glioma.

  2009cited by this paper
• Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma1

  2009cited by this paper
• Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.

  2008cited by this paper
• Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

  2008cited by this paper
• Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas

  2008cited by this paper
• A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

  2008cited by this paper
• Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.

  2008cited by this paper
• The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors

  2008cited by this paper
• Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy

  2008cited by this paper
• Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor.

  2008cited by this paper
• A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

  2008cited by this paper
• Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor

  2008cited by this paper
• Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

  2007cited by this paper
• Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

  2007cited by this paper
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

  2007cited by this paper
• Molecular mechanisms involved in T cell migration across the blood–brain barrier

  2006cited by this paper
• Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma.

  2006cited by this paper
• Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

  2006cited by this paper
• Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

  2006cited by this paper
• The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu.

  2006cited by this paper
• The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1

  2006cited by this paper
• A Prospective Randomized Trial Comparing the Efficacy and Adverse Effects of Four Recognized Treatments of Molluscum Contagiosum in Children

  2006cited by this paper
• A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma.

  2006cited by this paper
• The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.

  2005cited by this paper
• Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.

  2005cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• Radial glia cells are candidate stem cells of ependymoma.

  2005cited by this paper
• Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma

  2005cited by this paper
• EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

  2005cited by this paper
• Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas

  2005cited by this paper
• Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index

  2005cited by this paper
• Toll-like receptor 3 promotes cross-priming to virus-infected cells

  2005cited by this paper
• Autologous Glioma Cell Vaccine Admixed with Interleukin-4 Gene Transfected Fibroblasts in the Treatment of Recurrent Glioblastoma: Preliminary Observations in a Patient with a Favorable Response to Therapy

  2004cited by this paper
• Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

  2004cited by this paper
• Cytokine gene therapy for malignant glioma

  2004cited by this paper
• Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma.

  2004cited by this paper
• Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12

  2004cited by this paper
• Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma

  2004cited by this paper
• Prognostic significance of the immunohistochemical index of survivin in glioma : a comparative study with the MIB-1 index

  2004cited by this paper
• Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.

  2003cited by this paper
• T-cell immune responses in the brain and their relevance for cerebral malignancies.

  2003cited by this paper
• Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

  2003cited by this paper
• Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

  2003cited by this paper
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy

  2003cited by this paper
• Imiquimod is Highly Effective for Extensive, Hyperproliferative Condyloma in Children

  2003cited by this paper
• Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

  2002cited by this paper
• Influence of tumor grade on time to progression after irradiation for localized ependymoma in children.

  2002cited by this paper
• Preliminary results from a Phase II trail of conformal radiation therapy for pediatric patients with localised low-grade astrocytoma and ependymoma.

  2002cited by this paper
• Identification of a Novel HLA-A*0201-restricted, Cytotoxic T Lymphocyte Epitope in a Human Glioma-associated Antigen, Interleukin 13 Receptor α2 Chain

  2002cited by this paper
• Quantitatively determined survivin expression levels are of prognostic value in human gliomas.

  2002cited by this paper
• Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

  2001cited by this paper
• Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients.

  2001cited by this paper
• Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas.

  2001cited by this paper
• Gene Therapy of Malignant Gliomas: A Pilot Study of Vaccination with Irradiated Autologous Glioma and Dendritic Cells Admixed with IL-4 Transduced Fibroblasts to Elicit an Immune Response

  2001cited by this paper
• Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer.

  2001cited by this paper
• Molecular Expression Analysis of Restrictive Receptor for Interleukin 13 , a Brain Tumor-associated Cancer / Testis Antigen

  2000cited by this paper
• Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

  2000cited by this paper
• Eph receptors and ephrin ligands: embryogenesis to tumorigenesis

  2000cited by this paper
• Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis Antigen

  2000cited by this paper
• Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response.

  2000cited by this paper
• A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors.

  1999cited by this paper
• A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

  1999cited by this paper
• Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme.

  1999cited by this paper
• Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group.

  1998cited by this paper
• Prognostic Factors in Infants and Very Young Children with Intracranial Ependymomas

  1998cited by this paper
• Treatment of Intracranial Ependymoma by Surgery Alone

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma A report of the Children's Cancer Group

  1998cited by this paper
• Tumor-specific killer cells in paraneoplastic cerebellar degeneration

  1998cited by this paper
• Novel anti–brain tumor cytotoxins specific for cancer cells

  1998cited by this paper
• The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis

  1997cited by this paper
• Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood

  1997cited by this paper
• Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study.

  1996cited by this paper
• Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study.

  1996cited by this paper
• Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.

  1993cited by this paper
• Carboplatin in childhood brain tumors: A children's cancer study group phase II trial

  1990cited by this paper
• Journal of Translational Medicine Toll like Receptor-3 Ligand Poly-iclc Promotes the Efficacy of Peripheral Vaccinations with Tumor Antigen-derived Peptide Epitopes in Murine Cns Tumor Models

  year unknowncited by this paper

• Algorithm-based assessment of T-cell dysfunction and exclusion to forecast ICB sensitivity in pediatric brain ependymoma

  2025cites this paper
• Behavioral Improvements following Lesion Resection for Pediatric Epilepsy: Pediatric Psychosurgery?

  2023cites this paper
• Why haven't we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances.

  2023cites this paper
• Investigating The Potential for Immunotherapies in Diffuse Intrinsic Pontine Glioma (DIPG)

  2022cites this paper
• Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions

  2022cites this paper
• Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

  2021cites this paper
• Intracranial ependymomas: molecular insights and translation to treatment

  2020cites this paper
• Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma

  2017cites this paper
• Identification of glioma-associated antigens for brain tumor immunotherapy

  2015cites this paper
• The fine structure of ependymomas.

  2014cites this paper
• The fine structure of ependymomas REVIEW

  2014cites this paper
• STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

  2014cites this paper